Discover
ACHL
Achilles Therapeutics plc
1.48
undefined x undefined
undefined x undefined
bid
ask
+
0.01
0.68%
04:00 PM
| Ytd | 29.82% | |
| 1y | 14.73% |
1.45
day range
1.50
52 week range
| Open | 1.48 | Prev Close | 1.47 | Low | 1.45 | High | 1.50 | Mkt Cap | N/A |
| Vol | 1.20M | Avg Vol | 0.00 | EPS | N/A | P/E | N/A | Forward P/E | -0.61 |
| Beta | 1.34 | Short Ratio | 1.69 | Inst. Own | 59.30% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | N/A | 200-d Avg | N/A | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 20.42M | ||
| Research and Development Expense | 16.40M | ||
| Selling, General and Administrative Expense | 4.02M | ||
| Operating Income | -20.42M | ||
| Income Tax Expense | -5.00K | ||
| Net Income | -19.59M | ||
| Net Income Common Stock | -19.59M | ||
| Net Income Common Stock (USD) | -19.59M | ||
| Consolidated Income | -19.59M | ||
| Earnings per Basic Share | -0.48 | ||
| Earnings per Basic Share (USD) | -0.48 | ||
| Earnings per Diluted Share | -0.48 | ||
| Earning Before Interest & Taxes (EBIT) | -19.60M | ||
| Earning Before Interest & Taxes (USD) | -19.60M | ||
| Weighted Average Shares | 40.43M | ||
| Weighted Average Shares Diluted | 40.43M | ||
| Balance Sheet | |||
| Cash and Equivalents | 86.05M | ||
| Cash and Equivalents (USD) | 86.05M | ||
| Investments | 20.00K | ||
| Investments Non-Current | 20.00K | ||
| Current Assets | 111.63M | ||
| Property, Plant & Equipment Net | 9.23M | ||
| Total Assets | 122.68M | ||
| Debt Current | 3.62M | ||
| Total Debt | 3.62M | ||
| Current Liabilities | 18.47M | ||
| Total Liabilities | 19.54M | ||
| Accumulated Retained Earnings (Deficit) | -308.20M | ||
| Accumulated Other Comprehensive Income | -7.94M | ||
| Shareholders Equity | 103.14M | ||
| Shareholders Equity (USD) | 103.14M | ||
| Assets Non-Current | 11.05M | ||
| Total Debt (USD) | 3.62M | ||
| Liabilities Non-Current | 1.07M | ||
| Trade and Non-Trade Payables | 4.25M | ||
| Tax Assets | 41.00K | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.20M | ||
| Net Cash Flow from Financing | 4.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -9.09M | ||
| Capital Expenditure | -28.00K | ||
| Issuance (Purchase) of Equity Shares | 4.00K | ||
| Net Cash Flow from Investing | -28.00K | ||
| Net Cash Flow from Operations | -14.26M | ||
| Effect of Exchange Rate Changes on Cash | 5.19M | ||
| Share Based Compensation | 1.18M | ||